Ipamorelin binds selectively to ghrelin receptors (GHS-R1a) without triggering cortisol

Ipamorelin binds to ghrelin receptors (GHS-R1a) in the pituitary, triggering

Ipamorelin pharmacokinetics shows a 2-hour plasma half-life with rapid absorption

Ipamorelin biomarkers track GH pulse amplitude, IGF-1 response, cortisol stability,

Ipamorelin activates the ghrelin receptor in the pituitary, triggering pulsatile

Ipamorelin gene expression modulates growth hormone pathways through GHRH receptor

Ipamorelin downstream effects include sustained GH pulsatility, improved metabolic flexibility,

Ipamorelin bioavailability is approximately 3–8% when administered subcutaneously, requiring precise

Ipamorelin animal research shows clear GH release, but human trials

Tesamorelin activates pituitary GH receptors via GHRH signaling, triggering IGF-1

Tesamorelin receptor pharmacology activates GHRH receptors on pituitary somatotrophs, driving

Tesamorelin triggers pulsatile growth hormone release via GHRH receptor activation,

Ipamorelin metabolism research shows a 60–90 minute plasma half-life with

Tesamorelin has a plasma half-life of 26–38 minutes and reaches

Tesamorelin biomarkers track visceral adipose tissue reduction, IGF-1 elevation, and

Tesamorelin downstream effects include IGF-1 elevation, visceral fat reduction, and

Tesamorelin gene expression activates growth hormone-releasing hormone receptors, triggering pituitary

Tesamorelin bioavailability averages 4–5% via subcutaneous injection, varying with injection

Tesamorelin animal models focus on mechanisms; human trials measure clinical

Tesamorelin stimulates pulsatile GH release via GHRH receptor binding in

Tesamorelin + ipamorelin blend signaling pathway activates GHRH and ghrelin